Private company

REATA PHARMACEUTICALS INC

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies that change patients’ lives for the better. Our lead programs are omaveloxolone in a rare neurological disease called Friedreich’s ataxia (FA) and bardoxolone in rare forms of CKD.”68 It is headquartered in Plano, Texas.1

Last updated Oct 20, 2026.

Overview

$2.2MRevenue, fiscal 20222
-$311.9MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersPlano, Texas1
  • Incorporated inDE3
  • Business address5320 Legacy Drive, Plano, Tx 750243
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-14075.0%Net margin2
-80.7%Revenue growth, 20222
-$207.5MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$169.8M
  • Income tax0¢$25.0K

Out of $2.2M in revenue.2 The company lost money this year.

Financial statements

Revenue456782$2.2M in 2022−96% since 2015
0$20.0M$40.0M$60.0M2015: $50.3M$50.3M20152016: $49.9M$49.9M2016−1%2017: $48.1M$48.1M2017−4%2018: $53.6M$53.6M2018+12%2019: $26.5M$26.5M2019−51%2020: $9.0M$9.0M2020−66%2021: $11.5M$11.5M2021+27%2022: $2.2M$2.2M2022−81%
Net income456782-$311.9M in 2022+21410% since 2015
-$400.0M-$300.0M-$200.0M-$100.0M02015: -$1.4M-$1.4M20152016: -$6.2M-$6.2M2016+329%2017: -$47.7M-$47.7M2017+666%2018: -$80.5M-$80.5M2018+69%2019: -$290.2M-$290.2M2019+260%2020: -$247.8M-$247.8M2020−15%2021: -$297.4M-$297.4M2021+20%2022: -$311.9M-$311.9M2022+5%
Fiscal year20152016201720182019202020212022
Revenue$50.3M4$49.9M5$48.1M6$53.6M7$26.5M8$9.0M2$11.5M2$2.2M2
Research and development$35.1M4$39.5M5$71.3M6$97.3M7$128.1M8$159.1M2$156.0M2$169.8M2
Operating expenses$256.2M2$280.2M2
Interest$1.5M6$6.2M7$11.2M8$14.9M2$6.6M2$02
Income before tax-$297.8M2-$311.9M2
Income tax$1.1M4-$441.0K5$3.0K6$26.0K7$8.0K8-$22.5M2-$450.0K2-$25.0K2
Net income-$1.4M4-$6.2M5-$47.7M6-$80.5M7-$290.2M8-$247.8M2-$297.4M2-$311.9M2
Earnings per share-$0.094-$0.315-$1.996-$2.917-$9.548-$7.352-$8.192-$8.542
Earnings per share (diluted)-$0.094-$0.315-$1.996-$2.917-$9.548-$7.352-$8.192-$8.542
Shares (weighted, basic)36.3M shares236.5M shares2
Shares (weighted, diluted)36.3M shares236.5M shares2

Compare REATA PHARMACEUTICALS INC with another company

Corporate structure

REATA PHARMACEUTICALS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of REATA PHARMACEUTICALS INC

  • CPMG Inc Filed SC 13D/A on REATA PHARMACEUTICALS INC, latest Sep 28, 2023 (2 filings since Aug 1, 2023)
  • William Rose Filed SC 13D/A on REATA PHARMACEUTICALS INC, latest Sep 26, 2023 (4 filings since Jul 31, 2023)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G on REATA PHARMACEUTICALS INC, latest Jun 26, 2023
  • First Light Asset Management, LLC Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest May 15, 2023 (2 filings since Feb 14, 2023)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G on REATA PHARMACEUTICALS INC, latest Mar 7, 2023
  • Point72 Asset Management, L.P. Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest Feb 14, 2023 (2 filings since Sep 22, 2022)
  • EcoR1 Capital, LLC Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest Feb 10, 2023 (2 filings since Apr 11, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • Wellington Management Company Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest Sep 9, 2022 (2 filings since Feb 4, 2022)
  • Invesco Filed SC 13G/A on REATA PHARMACEUTICALS INC, latest Mar 10, 2022 (2 filings since Feb 10, 2022)
  • REATA PHARMACEUTICALS INC Plano, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What REATA PHARMACEUTICALS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$27.5M2 Dec 31, 2022$26.9M2 Dec 31, 2021+2.3%
Accumulated depreciation$16.3M2 Dec 31, 2022$15.3M2 Dec 31, 2021+6.8%
Property and equipment, net$11.2M2 Dec 31, 2022$11.6M2 Dec 31, 2021−3.7%
Operating-lease assets (leased space)$105.3M2 Dec 31, 2022$126.8M2 Dec 31, 2021−17.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$42.3M2 Dec 31, 2022$590.3M2 Dec 31, 2021−92.8%
Marketable securities, current$345.2M2 Dec 31, 2022$02 Dec 31, 2021

Leadership

Who has led REATA PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James Warren Huff2016–2023

President

  1. Manmeet Singh Soni2023

Chief financial officer

  1. Jason Douglas Wilson2016–2019
  2. Manmeet Singh Soni2019–2023

Chief operating officer

  1. Manmeet Singh Soni2020–2023
20202025
Board members and other officers (24)

Timeline

  1. Sep 26, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer42
  2. Sep 21, 20238-K Shareholder vote; Other events43
  3. Sep 12, 20238-K Other events44
  4. Jul 31, 20238-K Entered a material agreement; Other events45
  5. Jul 28, 20238-K Other events46
  6. Jul 11, 20238-K Entered a material agreement47
  7. Jun 20, 20238-K Entered a material agreement48
  8. Jun 7, 20238-K Shareholder vote49
  9. May 10, 20238-K Results of operations; Regulation FD disclosure50
  10. Mar 1, 20238-K Bylaws or fiscal year changed51
  11. Feb 28, 20238-K Regulation FD disclosure; Other events52
  12. Nov 8, 20228-K Results of operations; Regulation FD disclosure53
  13. Dec 8, 2016New chief executive James Warren Huff becomes CEO14

Calendar

When it reported results

  1. May 10, 2023Reported quarterly or annual results50
  2. Nov 8, 2022Reported quarterly or annual results53
  3. Aug 8, 2022Reported quarterly or annual results54
  4. May 10, 2022Reported quarterly or annual results55
  5. Feb 28, 2022Reported quarterly or annual results56
  6. Nov 8, 2021Reported quarterly or annual results57

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

219 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 22 major events, 104 insider forms, 22 large holders, 63 other. The latest 20:

  1. Oct 6, 202315-12G EDGAR
  2. Sep 28, 2023SC 13D/A EDGAR
  3. Sep 28, 20234 EDGAR
  4. Sep 26, 20238-K EDGAR
  5. Sep 26, 2023SC 13D/A EDGAR
  6. Sep 26, 2023POSASR EDGAR
  7. Sep 26, 2023S-8 POS EDGAR
  8. Sep 26, 2023S-8 POS EDGAR
  9. Sep 26, 2023S-8 POS EDGAR
  10. Sep 26, 2023S-8 POS EDGAR
  11. Sep 26, 2023S-8 POS EDGAR
  12. Sep 26, 2023S-8 POS EDGAR
  13. Sep 26, 2023S-8 POS EDGAR
  14. Sep 26, 2023S-8 POS EDGAR
  15. Sep 26, 2023S-8 POS EDGAR
  16. Sep 26, 2023S-8 POS EDGAR
  17. Sep 26, 20234 EDGAR
  18. Sep 26, 20234 FORM 4 SUBMISSION EDGAR
  19. Sep 26, 20234 FORM 4 SUBMISSION EDGAR
  20. Sep 26, 20234 FORM 4 SUBMISSION EDGAR

The 219 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

55 open-market trades by officers, directors and large owners since October 2021: 1 buys and 54 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2023Loewen AndreaSVP, Global Regulatory AffairsSale3,175$172.03$546.2KForm 4
Sep 5, 2023Anand BhaskarSVP, Chief Accounting OfficerSale406$169.20$68.7KForm 4
Aug 16, 2023WORTLEY MICHAEL DChief Legal OfficerSale398$168.76$67.2KForm 4
Aug 16, 2023Soni Manmeet SinghCOO, CFO and PresidentSale1,755$168.41$295.6KForm 4
Aug 16, 2023Meyer Colin JohnChief Innovation OfficerSale596$168.74$100.6KForm 4
Aug 16, 2023Bir Dawn CarterChief Commercial OfficerSale398$168.33$67.0KForm 4
Aug 16, 2023Anand BhaskarSVP, Chief Accounting OfficerSale210$168.42$35.4KForm 4
Aug 15, 2023WORTLEY MICHAEL DChief Legal OfficerSale807$169.04$136.4KForm 4
Aug 15, 2023Meyer Colin JohnChief Innovation OfficerSale2,144$169.07$362.5KForm 4
Aug 15, 2023Bir Dawn CarterChief Commercial OfficerSale807$169.04$136.4KForm 4
Aug 15, 2023Anand BhaskarSVP, Chief Accounting OfficerSale193$169.06$32.6KForm 4
Jul 28, 2023Soni Manmeet SinghCOO, CFO and PresidentSale75,000$164.62$12.3MForm 4
Jul 28, 2023Ruff ShamimDirectorSale8,235$164.53$1.4MForm 4
Jul 28, 2023McClellan William D. Jr.DirectorSale5,000$164.49$822.5KForm 4
Jul 28, 2023Bir Dawn CarterChief Commercial OfficerSale40,000$164.54$6.6MForm 4
Jun 14, 2023Anand BhaskarSVP, Chief Accounting OfficerSale2,343$102.11$239.2KForm 4
Jun 13, 2023Soni Manmeet SinghCOO, CFO and PresidentSale78,085$102.89$8.0MForm 4
Jun 12, 2023Soni Manmeet SinghCOO, CFO and PresidentSale4,711$99.62$469.3KForm 4
May 16, 2023WORTLEY MICHAEL DChief Legal OfficerSale417$80.99$33.8KForm 4
May 16, 2023Soni Manmeet SinghCOO, CFO and PresidentSale625$80.93$50.6KForm 4

All 55 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How REATA PHARMACEUTICALS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARREATA PHARMACEUTICALS INC1
  • CIK0001358762
  • Employer ID (EIN)11-36519451
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address5320 Legacy Drive, Plano, TX 750241
  • Phone972-865-22191
  • Public float$834.2M as of Jun 30, 20222
  • On EDGAR sinceMar 27, 20061
  • Filings702 in all: 4 (324), 8-K (86), SC 13D/A (43), 144 (35), 3 (30), SC 13G/A (23), 10-Q (22), DEFA14A (12)1
    All 43 form types

    SC 13G (12), S-8 (10), S-8 POS (10), 424B5 (9), CORRESP (8), DEF 14A (8), 10-K (7), 4/A (7), S-1/A (6), D (5), SC 13D (5), UPLOAD (5), REGDEX (4), DRSLTR (3), 5 (2), CT ORDER (2), DRS/A (2), EFFECT (2), S-1 (2), S-3ASR (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), DEFM14A (1), DRS (1), POSASR (1), PREM14A (1), RW (1), S-3 (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2023
    Quarterly report (10-Q) Aug 8, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Sep 26, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
    SEC EDGAROther events
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68